Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of litifilimab in active systemic lupus erythematosus on background standard of care
NL-OMON61073Phase 3Completed
- Sponsor
- Biogen
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Litifilimab + background standard of care with Placebo + background standard of care (2 arms). Primary endpoint: Percentage of participants who achieved an SRI-4 response at Week 52. Started May 2022; status: completed.
02
Drugs
litifilimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON61073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61073.